In short
Clinical trials for ROTAVIRUS SEROTYPE G1 HUMAN-BOVINE ROTAVIRUS REASSORTANTS (LIVE) PRODUCED ON VERO CELLS are being studied in young children in a vaccine research setting. The trial data shown here focuses on safety and immune response, especially in infants, toddlers, and children. These trials look at how well the vaccine works and how well it is tolerated.
Key points
- Clinical trial data for ROTAVIRUS SEROTYPE G1 HUMAN-BOVINE ROTAVIRUS REASSORTANTS (LIVE) PRODUCED ON VERO CELLS here is not provided in the source, so no rotavirus-specific trial results can be summarized from the available record. The only trial shown is a Phase 2 study in healthy infants, toddlers, and children for meningococcal immunization. It focuses on safety and immune response, including adverse events, injection site reactions, and antibody measures. The study is authorised and plans to enroll 750 participants. The listed outcomes are centered on how well the vaccine response can be measured in different age groups.
Trial overview
The source data provided for this article does not include a clinical trial that studies ROTAVIRUS SEROTYPE G1 HUMAN-BOVINE ROTAVIRUS REASSORTANTS (LIVE) PRODUCED ON VERO CELLS. Instead, the only trial listed is about meningococcal immunization in healthy young participants.
This trial is an interventional study, which means researchers give vaccines and then measure the results. The study compares MenPenta vaccine formulations with comparator vaccines and looks at both safety and immune response.
Study population and participation
The trial includes healthy children, toddlers, and infants. The brief summary says safety is described in children in Stage 1, toddlers in Stage 2, and infants in Stage 3.
For infants in Stage 3, the study measures immune response after the second dose at about 4 months of age and after the third dose at 12 to 15 months of age. For children and toddlers, immune response is measured at each time point after vaccination.
Trial phase and status
The study is a Phase 2 trial. Phase 2 studies are used to learn more about safety and how well the immune system responds in a larger group than early-stage trials.
The status of the trial is Authorised, and the planned enrollment is 750 participants.
Outcomes measured
The trial measures several safety outcomes, including unsolicited immediate adverse events, solicited injection site reactions, systemic reactions, unsolicited adverse events, and serious adverse events. These are used to see how well the vaccine is tolerated after vaccination.
The trial also measures immune response using tests such as hSBA, vaccine seroresponse, and geometric mean titers for meningococcal serogroups A, C, W, Y, and reference MenB strains. These tests check whether the body makes antibodies that may help protect against disease.
Other outcomes include the percentage of participants with antibody levels at or above the lower limit of quantification and the percentage with antibody titers at specific cutoffs against MenB strains. These measurements help researchers compare immune responses across age groups and doses.
What the trial data shows
The data provided here shows a vaccine study focused on meningococcal disease prevention, not a rotavirus study. It includes multiple age groups and uses both safety and immune response endpoints to judge the vaccine formulations.
No rotavirus-specific trial details, endpoints, or participant groups were included in the source material for ROTAVIRUS SEROTYPE G1 HUMAN-BOVINE ROTAVIRUS REASSORTANTS (LIVE) PRODUCED ON VERO CELLS.